About Eikon Therapeutics
Eikon Therapeutics is a private company based in Hayward, California. It has reported $1,111,762,386 raised in four offerings on Form D since May 2021. Its chief executive is Roger Perlmutter.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2025 | Feb 28, 2025 | $350,700,037of $399.9M target | 27 | $12.9M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 18, 2023 | Jun 1, 2023 | $140,759,782of $534.9M target | 21 | $6.7M | EquityRule 506(b) | Form D ↗ |
| Dec 3, 2021 | Jan 6, 2022 | $517,764,785of $524.9M target | 43 | $12.0M | EquityRule 506(b) | Form D ↗ |
| May 4, 2021 | May 13, 2021 | $102,537,782of $107.8M target | 12 | $8.5M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $1,111,762,386 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Eikon Therapeutics's Form D filed Feb 28, 2025.
Earlier filings also listed Russ Berman (executive officer, last listed Jun 2023), Roy Banes (executive officer, last listed Jun 2023), Josh Wolfe (director, last listed Jun 2023), Dan Anderson (executive officer, last listed Jun 2023), Benjamin Thorner (executive officer, last listed Jun 2023), Barbara Howes (executive officer, last listed Jun 2023), Ashish Kheterpal (executive officer, last listed Jun 2023) and Alfred Bowie (executive officer, last listed Jun 2023).